Amphastar Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 ($1,235.2 Mil) to Dec. 2025 ($1,222.4 Mil) and
declined
from Dec. 2025 ($1,222.4 Mil) to Mar. 2026 ($874.4 Mil).
Amphastar Pharmaceuticals's annual market cap
declined
from Dec. 2023 ($2,973.1 Mil) to Dec. 2024 ($1,768.1 Mil) and
declined
from Dec. 2024 ($1,768.1 Mil) to Dec. 2025 ($1,222.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amphastar Pharmaceuticals's Enterprise Value for Today is $1,321.0 Mil.
Amphastar Pharmaceuticals (NAS:AMPH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Amphastar Pharmaceuticals Market Cap Related Terms
Amphastar Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Market Cap of $926.6 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amphastar Pharmaceuticals and its competitors. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #273 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Amphastar Pharmaceuticals' Market Cap too high?
Amphastar Pharmaceuticals' current Market Cap is $926.6 Mil. The Drug Manufacturers industry median Market Cap is 206.50. Amphastar Pharmaceuticals' value of $926.6 Mil is 348.7% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #273 out of 1023 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Market Cap compare to ETON and ESPR?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #273 out of 1023 companies for Market Cap. This puts Amphastar Pharmaceuticals in the upper half of its industry. The industry median Market Cap is 206.50. Amphastar Pharmaceuticals' value of $926.6 Mil is 348.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Market Cap of $926.6 Mil is 348.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Market Cap is $926.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.78, compared to a current price of $21.02 — trading 56.9% below its estimated fair value. The current Market Cap is $926.6 Mil and 348.7% above the Drug Manufacturers industry median of 206.50. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Market Cap is $926.6 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.02 is trading 56.9% below its estimated GF Value™ of $48.78.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Market Cap: $926.6 Mil
GF Value™: $48.78 vs. price of $21.02 (56.9% below fair value)
Industry Position: 348.7% above the Drug Manufacturers median (#273 of 1023)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
